Skip to main content
رجوع
CSMYF logo

COSMOS Pharmaceutical Corporation

جودة البيانات: 100%
ذروة شراء
CSMYF
OTC Healthcare Medical - Pharmaceuticals
KWD 48.27
KWD 0.00 (0.00%)
القيمة السوقية: 3.83B
نطاق اليوم
KWD 48.27 KWD 61.39
نطاق 52 أسبوعًا
KWD 46.06 KWD 61.39
حجم التداول
500
متوسط 50 يوم / 200 يوم
KWD 48.27 / KWD 46.91
الإغلاق السابق
KWD 48.27

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E 0.1 0.4
P/B 0.0 2.9
ROE % 12.7 3.7
Net Margin % 3.1 3.9
Rev Growth 5Y % 8.6 10.0
D/E 0.2 0.2

السعر المستهدف للمحللين

لا تتوفر تغطية محللين

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 527.585
KWD 518.459 – KWD 539.593
1400 B 1
FY2029 KWD 503.407
KWD 494.700 – KWD 514.865
1300 B 1
FY2028 KWD 444.779
KWD 437.086 – KWD 454.902
1200 B 1

النقاط الرئيسية

Revenue grew 8.63% annually over 5 years — modest growth
Earnings grew 26.68% over the past year
ROE of 12.67% — decent returns on equity
Debt/Equity of 0.19 — conservative balance sheet
Negative free cash flow of -859.00M
P/E of 0.12 — trading at a low valuation

النمو

Revenue Growth (5Y)
8.63%
Revenue (1Y)4.81%
Earnings (1Y)26.68%
FCF Growth (3Y)N/A

الجودة

Return on Equity
12.67%
ROIC9.86%
Net Margin3.06%
Op. Margin3.99%

الأمان

Debt / Equity
0.19
Current Ratio0.75
Interest Coverage159.07

التقييم

P/E Ratio
0.12
P/B Ratio0.01
EV/EBITDA-0.08
Dividend Yield0.01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 4.81% Revenue Growth (3Y) 10.54%
Earnings Growth (1Y) 26.68% Earnings Growth (3Y) 14.09%
Revenue Growth (5Y) 8.63% Earnings Growth (5Y) 3.35%
Profitability
Revenue (TTM) 1.01T Net Income (TTM) 30.98B
ROE 12.67% ROA 5.90%
Gross Margin 21.09% Operating Margin 3.99%
Net Margin 3.06% Free Cash Flow (TTM) -859.00M
ROIC 9.86% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.19 Current Ratio 0.75
Interest Coverage 159.07 Dividend Yield 0.01%
Valuation
P/E Ratio 0.12 P/B Ratio 0.01
P/S Ratio 0.00 PEG Ratio 0.63
EV/EBITDA -0.08 Dividend Yield 0.01%
Market Cap 3.83B Enterprise Value -3.26B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1.01T 964.99B 827.70B 755.41B 726.42B
Net Income 30.98B 24.45B 23.80B 23.16B 27.16B
EPS (Diluted) 390.86 308.61 600.95 584.74 685.77
Gross Profit 213.28B 188.31B 168.72B 151.45B 145.11B
Operating Income 40.40B 31.50B 30.13B 29.80B 33.15B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 524.76B 476.55B 420.97B 363.05B 341.32B
Total Liabilities 267.29B 245.11B 209.90B 172.55B 170.74B
Shareholders' Equity 257.46B 231.44B 211.07B 190.51B 170.58B
Total Debt 49.96B 34.06B 18.20B 9.41B 10.44B
Cash & Equivalents 57.04B 52.30B 45.93B 37.36B 55.11B
Current Assets 165.62B 154.33B 137.09B 115.47B 125.13B
Current Liabilities 220.68B 213.23B 192.05B 162.06B 159.54B

درجات الاستراتيجيات

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches

النشاط الأخير

دخل Defensive Investing (Benjamin Graham)
Mar 24, 2026